欧洲失代偿期肝硬化及慢加急性肝衰竭患者的多重耐药细菌感染
该研究前瞻性评估欧洲两系列失代偿期肝硬化住院患者:2011年Canonic系列1146例中455例发生520次感染(39.7%),培养阳性者29.2%为多重耐药菌(MDROs);2017-2018年第二系列883例中284例发生392次感染,MDROs占23%,培养阳性者38%。MDRO感染与预后不良及三代头孢/喹诺酮类抗生素策略失败相关。
要点
- 失代偿期肝硬化住院患者感染发生率高,2011年系列为39.7%(455/1146例,520次感染)。
- MDROs在培养阳性感染中占比:2011年系列29.2%,2017-2018年系列38%(总感染中23%)。
- 院内感染(OR 2.74)、ICU入住(OR 2.09)、近期住院(OR 1.93)为MDR感染独立预测因素。
核心结论
- 多重耐药细菌感染是欧洲失代偿期肝硬化及慢加急性肝衰竭患者中普遍、增长且复杂的医疗问题,对预后产生负面影响。
- 作者认为,旨在预防肝硬化中抗生素耐药传播的策略应紧急评估。
研究设计与样本
- 前瞻性评估两系列失代偿期肝硬化住院患者:2011年Canonic系列纳入北、南、西欧1146例;2017-2018年第二系列纳入东、南、西欧883例。
- 评估内容包括流行病学、细菌感染临床特征、微生物学及经验性抗生素方案。
主要发现
- 第一系列455例发生520次感染(39.7%),以自发性细菌性腹膜炎、尿路感染和肺炎最常见,院内感染占主导。
- 第一系列近半数感染培养阳性,其中29.2%由MDROs引起;产超广谱β-内酰胺酶肠杆菌科为最常见MDROs,但各国及中心间患病率和类型差异显著。
- 抗生素耐药与不良预后及基于三代头孢菌素或喹诺酮类的抗生素策略失败相关。
- 院内感染(OR 2.74;p < 0.001)、ICU入住(OR 2.09;p = 0.02)、近期住院(OR 1.93;p = 0.04)为MDR感染独立预测因素。
- 第二系列MDROs患病率为23%(392次感染/284例),培养阳性感染中为38%;该系列观察到碳青霉烯耐药肠杆菌科比率轻度增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antibiotic resistance has been increasingly reported in patients with decompensated cirrhosis in single-center studies. Prospective investigations reporting broad epidemiological data are scarce. We aimed to analyze epidemiological changes in bacterial infections in patients with decompensated cirrhosis. METHODS: This was a prospective evaluation of 2 series of patients hospitalized with decompensated cirrhosis. The Canonic series included 1,146 patients from Northern, Southern and Western Europe in 2011. Data on epidemiology, clinical characteristics of bacterial infections, microbiology and empirical antibiotic schedules were assessed. A second series of 883 patients from Eastern, Southern and Western Europe was investigated between 2017-2018. RESULTS: A total of 455 patients developed 520 infections (39.7%) in the first series, with spontaneous bacterial peritonitis, urinary tract infections and pneumonia the most frequent infections. Nosocomial episodes predominated in this series. Nearly half of the infections were culture-positive, of which 29.2% were caused by multidrug-resistant organisms (MDROs). MDR strains were more frequently isolated in Northern and Western Europe. Extended-spectrum beta-lactamase-producing Enterobacteriaceae were the most frequent MDROs isolated in this series, although prevalence and type differed markedly among countries and centers. Antibiotic resistance was associated with poor prognosis and failure of antibiotic strategies, based on third-generation cephalosporins or quinolones. Nosocomial infection (odds ratio [OR] 2.74; p < 0.001), intensive care unit admission (OR 2.09; p = 0.02), and recent hospitalization (OR 1.93; p = 0.04) were identified as independent predictors of MDR infection. The prevalence of MDROs in the second series (392 infections/284 patients) was 23%; 38% in culture-positive infections. A mild increase in the rate of carbapenem-resistant Enterobacteriaceae was observed in this series. CONCLUSIONS: MDR bacterial infections constitute a prevalent, growing and complex healthcare problem in patients with decompensated cirrhosis and acute-on-chronic liver failure across Europe, negatively impacting on prognosis. Strategies aimed at preventing the spread of antibiotic resistance in cirrhosis should be urgently evaluated. LAY SUMMARY: Infections caused by bacteria resistant to the main antibiotic families are prevalent in patients with cirrhosis. This study demonstrates that this healthcare problem is increasing and extends through all European regions. Infections caused by these difficult to treat bacteria resolve less frequently and often cause the death of the patient. The type of resistant bacteria varies markedly among different hospitals.
引用
- Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2018. PMID: 30391380. doi:10.1016/j.jhep.2018.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。